Routine prophylaxis with intravenous (IV) C1‐INH concentrate has been shown to reduce HAE attack frequency (Bernstein et al., 2014; Zuraw et al., 2010) and improve quality of life in patients (Greeve et al., 2016; Lumry, Miller, Newcomer, Fitts, & Dayno, 2014). This evidence concerns the gene SERPING1 and hereditary angioedema.